Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Diagnostic complexities of eosinophilia.

Montgomery ND, Dunphy CH, Mooberry M, Laramore A, Foster MC, Park SI, Fedoriw YD.

Arch Pathol Lab Med. 2013 Feb;137(2):259-69. doi: 10.5858/arpa.2011-0597-RA. Review.

PMID:
23368869
2.

[Characteristics of cytogenetics and molecular biology in patients with eosinophilia].

Qu SQ, Ai XF, Li CW, Li QH, Xu ZF, Qin TJ, Zhang Y, Xiao ZJ.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2012 Oct;20(5):1216-20. Chinese.

PMID:
23114151
3.

Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.

Tefferi A, Gotlib J, Pardanani A.

Mayo Clin Proc. 2010 Feb;85(2):158-64. doi: 10.4065/mcp.2009.0503. Review.

4.
5.

Eosinophilia: secondary, clonal and idiopathic.

Tefferi A, Patnaik MM, Pardanani A.

Br J Haematol. 2006 Jun;133(5):468-92. Review.

PMID:
16681635
6.

Molecular classification and pathogenesis of eosinophilic disorders: 2005 update.

Gotlib J.

Acta Haematol. 2005;114(1):7-25. Review.

PMID:
15995322
7.

The FIP1L1-PDGFRalpha kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia.

Cools J, Stover EH, Wlodarska I, Marynen P, Gilliland DG.

Curr Opin Hematol. 2004 Jan;11(1):51-7. Review.

PMID:
14676627
8.

[Hematological disorders and hypereosinophilias].

Malfuson JV, Fagot T, Konopacki J, Mangouka L, Souleau B, de Revel T.

Rev Med Interne. 2009 Apr;30(4):322-30. doi: 10.1016/j.revmed.2008.10.019. French.

PMID:
19201511
9.

KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities.

Maric I, Robyn J, Metcalfe DD, Fay MP, Carter M, Wilson T, Fu W, Stoddard J, Scott L, Hartsell M, Kirshenbaum A, Akin C, Nutman TB, Noel P, Klion AD.

J Allergy Clin Immunol. 2007 Sep;120(3):680-7.

PMID:
17628645
10.

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy.

Pardanani A, Ketterling RP, Brockman SR, Flynn HC, Paternoster SF, Shearer BM, Reeder TL, Li CY, Cross NC, Cools J, Gilliland DG, Dewald GW, Tefferi A.

Blood. 2003 Nov 1;102(9):3093-6.

11.
13.
14.

Eosinophilia in Hematologic Disorders.

Falchi L, Verstovsek S.

Immunol Allergy Clin North Am. 2015 Aug;35(3):439-52. doi: 10.1016/j.iac.2015.04.004. Review.

15.

Management of F/P+/- hypereosinophilic syndromes: case report and treatment review.

Kalra A, Palaniswamy C, Kalra A, Wig N, Sood R.

Am J Ther. 2012 Sep;19(5):e146-51. doi: 10.1097/MJT.0b013e3181ee7370.

PMID:
20724910
16.

Unique association of myeloid neoplasm with eosinophilia and abnormalities of PDGFRA with TTP.

Chaudhary LN, Bailey NG, Vos JA, Stotler CJ.

W V Med J. 2013 Mar-Apr;109(2):6-9.

PMID:
23600098
17.

Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: a review.

Savage N, George TI, Gotlib J.

Int J Lab Hematol. 2013 Oct;35(5):491-500. doi: 10.1111/ijlh.12057. Review.

PMID:
23489324
18.

The hypereosinophilic syndrome: fluorescence in situ hybridization detects the del(4)(q12)-FIP1L1/PDGFRA but not genomic rearrangements of other tyrosine kinases.

La Starza R, Specchia G, Cuneo A, Beacci D, Nozzoli C, Luciano L, Aventin A, Sambani C, Testoni N, Foppoli M, Invernizzi R, Marynen P, Martelli MF, Mecucci C.

Haematologica. 2005 May;90(5):596-601.

19.

[Disorders with eosinophilia, treatment of hypereosinophilic syndrome].

Borbényi Z.

Orv Hetil. 2005 May 1;146(18 Suppl 1):911-6. Review. Hungarian.

PMID:
15921304
20.

Chronic eosinophilic leukemias and the myeloproliferative variant of the hypereosinophilic syndrome.

Bain BJ, Fletcher SH.

Immunol Allergy Clin North Am. 2007 Aug;27(3):377-88. Review.

PMID:
17868855
Items per page

Supplemental Content

Support Center